HiberCell Email Format
Biotechnology ResearchNew York, United States11-50 Employees
HiberCell is a clinical-stage biotechnology company focused on oncology, pursuing first-in-class therapies that modulate adaptive stress pathways and anti-tumor immunity. Its candidates HC-5404 and HC-7366 target the stress response kinases PERK and GCN2, while odetiglucan is in Phase 2 to influence the anti-tumor innate immune response. The approach aims to address cancer relapse, metastasis, and treatment resistance. Based in New York City, New York, the company operates with a small, specialized team. In February 2024, HiberCell announced the launch of the QuAD[3] Platform, a Quantum Artificial Intelligence Drug Discovery and Development platform.